Eminent Venture Capital
5
28M
5
3
- Areas of investment
Summary
The top amount of exits for fund were in 2016. Deals in the range of 10 - 50 millions dollars are the general things for fund. Comparing to the other companies, this Eminent Venture Capital performs on 4 percentage points more the average number of lead investments. The important activity for fund was in 2007. The fund is constantly included in less than 2 deals per year.
The standard case for the fund is to invest in rounds with 7-8 partakers. Despite the Eminent Venture Capital, startups are often financed by WI Harper Group, Sycamore Ventures, NanoDimension. The meaningful sponsors for the fund in investment in the same round are NanoDimension, Flagship Pioneering, RUSNANO. In the next rounds fund is usually obtained by Sycamore Ventures, PTV Healthcare Capital, Novo Holdings.
We can highlight the next thriving fund investment areas, such as Biopharma, Pharmaceutical. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Cardiva Medical, GlobeImmune, Nereus Pharmaceuticals The fund has no exact preference in some founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low.
Investments analytics
Analytics
- Total investments
- 5
- Lead investments
- 0
- Exits
- 3
- Investments by industry
- Biotechnology (5)
- Medical (3)
- Health Care (3)
- Therapeutics (2)
- Drug Discovery (2) Show 5 more
- Investments by region
-
- United States (6)
- Peak activity year
- 2007
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 18
- Avg. valuation at time of investment
- 95M
- Group Appearance index
- 1.00
- Avg. company exit year
- 19
- Avg. multiplicator
- 2.62
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Tarveda Therapeutics | 07 Jan 2015 | Biotechnology, Health Care, Health Diagnostics, Medical, Therapeutics | Early Stage Venture | 21M | United States, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.